Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18951543 | PLEUROMUTILIN DERIVATIVE CONTAINING A THIAZOLO[5,4-C]PYRIDINE SIDE CHAIN, AND A PREPARATION METHOD AND APPLICATION THEREOF | November 2024 | March 2025 | Allow | 4 | 0 | 1 | No | No |
| 18429785 | System and method for non-surgical treatment of prolapsed hemorrhoids | February 2024 | March 2025 | Allow | 13 | 1 | 3 | Yes | No |
| 18406732 | METHODS OF TREATING CONDITIONS RELATED TO THE S1P1 RECEPTOR | January 2024 | March 2025 | Allow | 14 | 1 | 0 | No | No |
| 18382307 | TREATMENT OF HAIR LOSS DISORDERS WITH DEUTERATED JAK INHIBITORS | October 2023 | January 2025 | Allow | 15 | 2 | 1 | Yes | No |
| 18472660 | Apixaban Dosing | September 2023 | January 2025 | Allow | 16 | 1 | 3 | Yes | No |
| 18324359 | METHODS FOR TREATING VIRAL DISORDERS | May 2023 | June 2025 | Abandon | 25 | 0 | 1 | No | No |
| 18315285 | INHIBITION OF OLIG2 ACTIVITY | May 2023 | June 2025 | Abandon | 25 | 0 | 1 | No | No |
| 18133176 | METHODS OF TREATING SUICIDALITY | April 2023 | June 2025 | Allow | 26 | 4 | 0 | No | No |
| 18125800 | METHOD OF PREPARING LOXAPINE FILM ORAL DOSAGE FORM | March 2023 | June 2025 | Abandon | 27 | 3 | 0 | No | No |
| 17529791 | FULVESTRANT FORMULATIONS | November 2021 | March 2025 | Allow | 40 | 4 | 0 | Yes | No |
| 17529609 | CANCER TREATMENT MODALITIES | November 2021 | March 2025 | Abandon | 40 | 0 | 1 | No | No |
| 17325937 | METHODS OF TREATING CANCERS | May 2021 | April 2025 | Allow | 47 | 3 | 2 | No | No |
| 17257458 | Oral Pharmaceutical Formulations of Bitter Compounds for Pulmonary Hypertension | December 2020 | November 2024 | Allow | 46 | 2 | 1 | No | No |
| 17059297 | NUPR1 INHIBITION FOR TREATING CANCER | November 2020 | September 2024 | Abandon | 45 | 1 | 1 | No | No |
| 16343681 | DUAL INHIBITORS OF VISTA AND PD-1 PATHWAYS | April 2019 | April 2025 | Abandon | 60 | 7 | 1 | No | Yes |
| 16342730 | COMPOSITIONS AND METHODS FOR INHIBITING KINASES | April 2019 | June 2025 | Allow | 60 | 4 | 1 | Yes | Yes |
| 15561390 | P38 MAP KINASE INHIBITORS FOR TREATING FRIEDREICH�S ATAXIA | September 2017 | March 2025 | Allow | 60 | 7 | 1 | Yes | Yes |
| 14858029 | SUBSTITUTED N-(1H-INDAZOL-4-YL)IMIDAZO[1,2-a]PYRIDINE-3-CARBOXAMIDE COMPOUNDS AS TYPE III RECEPTOR TYROSINE KINASE INHIBITORS | September 2015 | June 2017 | Allow | 24 | 1 | 1 | No | No |
| 14233228 | Histone Deacetylase 6 Selective Inhibitors for the Treatment of Bone Disease | April 2014 | July 2016 | Allow | 30 | 2 | 1 | No | No |
| 14351360 | BIOCIDAL COMPOSITIONS AND METHODS OF USE | April 2014 | August 2016 | Allow | 28 | 2 | 1 | No | No |
| 14234916 | NOVEL ESTROGEN RECEPTOR LIGANDS | April 2014 | October 2016 | Allow | 33 | 2 | 1 | No | No |
| 14189543 | COMPOSITION FOR ELIMINATION OF TROUBLESOME VARMINTS | February 2014 | November 2016 | Allow | 33 | 3 | 0 | No | No |
| 14131849 | C-3 SUBSTITUTED BICYCLOOCTANE BASED HIV PROTEASE INHIBITORS | January 2014 | December 2015 | Allow | 23 | 1 | 1 | No | No |
| 14005462 | DERIVATIVES OF CELEBOXIB, USE THEREOF AND PREPARATION THEREOF | December 2013 | March 2016 | Allow | 30 | 2 | 1 | Yes | No |
| 14009969 | SMALL MOLECULES FOR TREATING BREAST CANCER | November 2013 | February 2016 | Allow | 28 | 2 | 1 | No | No |
| 14053736 | HETEROARYL LINKED QUINOLINYL MODULATORS OF RORgammat | October 2013 | October 2015 | Allow | 24 | 1 | 1 | No | No |
| 13884900 | Cyanoenamines and their use as fungicides | July 2013 | June 2016 | Allow | 37 | 3 | 1 | No | No |
| 13994048 | SUBSTITUTED N-(1H-INDAZOL-4-YL)IMIDAZO[1,2-a]PYRIDINE-3-CARBOXAMIDE COMPOUNDS AS TYPE III RECEPTOR TYROSINE KINASE INHIBITORS | June 2013 | June 2015 | Allow | 24 | 2 | 1 | Yes | No |
| 13883038 | Antimalarial Drug Comprising Alaremycin or Derivative Thereof as Active Ingredient | May 2013 | December 2015 | Allow | 31 | 1 | 1 | No | No |
| 13829062 | BORONIC ACID DERIVATIVES AND THERAPEUTIC USES THEREOF | March 2013 | July 2015 | Allow | 28 | 2 | 1 | Yes | No |
| 13558491 | Method of Lowering Serum Uric Acid Levels With (S)-Tofisopam | July 2012 | March 2016 | Allow | 44 | 2 | 1 | Yes | No |
| 13393436 | PHTHALANILATE COMPOUNDS AND METHODS OF USE | May 2012 | May 2014 | Allow | 27 | 0 | 2 | No | No |
| 13467764 | Inhibitors of PFKFB3 for Cancer Therapy | May 2012 | June 2016 | Allow | 49 | 4 | 1 | Yes | No |
| 13386199 | FUSED AMINODIHYDROPYRIMIDONE DERIVATIVES | April 2012 | May 2015 | Allow | 39 | 3 | 1 | Yes | No |
| 13389504 | PYRIMIDONE COMPOUNDS | April 2012 | September 2014 | Allow | 31 | 2 | 1 | No | No |
| 13440113 | (1,2,3-Triazolyl)sulfonyl Derivatives | April 2012 | March 2014 | Allow | 24 | 1 | 1 | Yes | No |
| 13381583 | L-SERINE TO BE USED AS A DRUG FOR PREVENTING AND/OR TREATING AN INFLAMMATORY RESPONSE OF THE SKIN | March 2012 | May 2018 | Allow | 60 | 9 | 1 | Yes | Yes |
| 13368468 | AROMATIC AND AROMATIC/HETEROAROMATIC MOLECULAR STRUCTURES WITH CONTROLLABLE ELECTRON CONDUCTING PROPERTIES | February 2012 | September 2014 | Allow | 31 | 2 | 1 | Yes | No |
| 13360066 | HETEROCYCLIC COMPOUND | January 2012 | February 2015 | Allow | 36 | 3 | 1 | No | No |
| 13176851 | COMPOSITIONS DERIVED FROM METATHESIZED NATURAL OILS AND AMINES AND METHODS OF MAKING | July 2011 | December 2015 | Allow | 53 | 3 | 2 | No | No |
| 13111993 | ORALLY DISINTEGRATING TABLETS OF ZOLMITRIPTAN AND PROCESS FOR PREPARING THE SAME | May 2011 | September 2014 | Allow | 40 | 3 | 1 | No | No |
| 11885946 | Antipruritic Agent for Pruritus Caused by Multiple Sclerosis | May 2008 | February 2015 | Allow | 60 | 6 | 1 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner LEE, ANDREW P.
With a 100.0% reversal rate, the PTAB has reversed the examiner's rejections more often than affirming them. This reversal rate is in the top 25% across the USPTO, indicating that appeals are more successful here than in most other areas.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 20.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner LEE, ANDREW P works in Art Unit 1691 and has examined 39 patent applications in our dataset. With an allowance rate of 84.6%, this examiner has an above-average tendency to allow applications. Applications typically reach final disposition in approximately 31 months.
Examiner LEE, ANDREW P's allowance rate of 84.6% places them in the 55% percentile among all USPTO examiners. This examiner has an above-average tendency to allow applications.
On average, applications examined by LEE, ANDREW P receive 2.56 office actions before reaching final disposition. This places the examiner in the 87% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by LEE, ANDREW P is 31 months. This places the examiner in the 34% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +25.0% benefit to allowance rate for applications examined by LEE, ANDREW P. This interview benefit is in the 75% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 21.9% of applications are subsequently allowed. This success rate is in the 18% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 60.9% of cases where such amendments are filed. This entry rate is in the 83% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 1% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.
This examiner withdraws rejections or reopens prosecution in 75.0% of appeals filed. This is in the 59% percentile among all examiners. Of these withdrawals, 66.7% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.
When applicants file petitions regarding this examiner's actions, 50.0% are granted (fully or in part). This grant rate is in the 59% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 3% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 3% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.